Liso-Cel Shows Promise in Relapsed/Refractory Large B-Cell Lymphoma

Lisocabtagene maraleucel demonstrated an objective response rate of 73% and a complete response rate of 53%, with the time to first CR or partial response occurring at a median of 1 month in patients with aggressive relapsed/refractory large B-cell lymphoma.

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL

Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo, in patients ≥70 years old with indolent non-Hodgkin lymphoma.